Atea Pharmaceuticals Inc. (AVIR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Atea Pharmaceuticals Inc. (AVIR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.15

-0.05 (-1.56%)

At close: Jan 14, 2025, 3:59 PM

3.15

-0.16%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3
Market Cap	266.48M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.03
PE Ratio (ttm)	-1.55
Forward PE	n/a
Analyst	Hold

Ask	3.45
Volume	379,224
Avg. Volume (20D)	331,190
Open	3.21
Previous Close	3.20
Day's Range	3.11 - 3.25
52-Week Range	2.75 - 4.60
Beta	undefined

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 30, 2020

Employees 75

Stock Exchange NASDAQ

Ticker Symbol AVIR

Website https://ateapharma.com

Analyst Forecast

According to 1 analyst ratings, the average rating for AVIR stock is "Hold." The 12-month stock price forecast is $6.88, which is an increase of 118.07% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

News

3 weeks ago · businesswire.com

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the “Concerned Shareholder Group” or “we”), who collective...

1 month ago · benzinga.com

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

On Wednesday, Atea Pharmaceuticals, Inc. AVIR released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to ...

1 month ago · zacks.com

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jea...

3 months ago · zacks.com

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.

3 months ago · zacks.com

New Strong Buy Stocks for October 16th

CLPR, REE, HMY, AVIR and WPRT have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2024.